The cardiac marker testing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Cardiac Marker Testing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The cardiac marker testing market size has grown rapidly in recent years. It will grow from $5.92 billion in 2023 to $6.52 billion in 2024 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to rise in geriatric population, rise in educational campaigns, increasing awareness, rising healthcare infrastructure, and rising patient population.
The cardiac marker testing market size is expected to see rapid growth in the next few years. It will grow to $9.35 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising incidences of cardiovascular diseases, increasing strategic collaborations and partnerships, increasing research and development initiatives, favorable reimbursement policies and rising demand for point-of-care (POC) testing. Major trends in the forecast period include advanced diagnostic technologies, automated analyzers, advanced cardiac marker testing assays, digital health technologies, and emergence of integrative technologies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/cardiac-marker-testing-global-market-report
Scope Of Cardiac Marker Testing Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Cardiac Marker Testing Market Overview
Market Drivers –
The rising incidence of cardiovascular diseases is expected to propel the growth of the cardiac marker testing market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The rising cases of cardiovascular diseases are caused due to an unhealthy diet, physical inactivity, tobacco use, harmful use of alcohol, and air pollution. Cardiac marker testing is required for cardiovascular diseases to accurately diagnose, assess the severity, and monitor the progression or response to treatment of heart conditions by detecting specific biomarkers released during myocardial injury. For instance, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, up 4.0% from 224.4 per 100,000 when compared to 2023. Sudden cardiac arrest was responsible for 20,114 deaths in the U.S. in 2021. Therefore, the rising incidence of cardiovascular diseases drives the cardiac marker testing market.
Market Trends –
Major companies operating in the cardiac marker testing market are focused on developing technologically advanced products, such as cardiac assays, to provide valuable, precise information about heart health and function. Cardiac assays are diagnostic tests designed to measure biomarkers or other indicators in the blood or other samples to assess heart function, diagnose cardiovascular diseases, or evaluate the risk of heart-related conditions. For instance, in October 2023, Mindray, a China-based medical device company, launched the troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTnI assay distinguishes itself with exceptional sensitivity, precision, and reliability, surpassing minimum requirements by achieving a 93% detection rate between the limit of detection (LoD) and the 99th percentile upper reference limit (URL) and maintaining an imprecision coefficient of variation (CV) below 5% at the 99th URL, making it highly effective in detecting myocardial injury. Mindray’s NT-proBNP assay is an important cardiac marker for heart failure, showing high precision with a coefficient of variation (CV) of =5%. It also effectively minimizes interference from 55 common heart disease medications, ensuring accurate detection and management of heart failure.
The cardiac marker testing market covered in this report is segmented –
1) By Product: Reagents And Kits, Instruments
2) By Biomarker Type: Troponin I And T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Other Cardiac Biomarkers
3) By Application: Laboratory Testing Facilities, Point-Of-Care Testing Facilities, Academic Institutions
Get an inside scoop of the cardiac marker testing market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19358&type=smp
Regional Insights –
North America was the largest region in the cardiac marker testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the cardiac marker testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., Guangzhou Wondfo Biotech Co. Ltd., Randox laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Kainos Medicine Inc., Alere Inc., Nano-Ditech Corporation, 1Drop Diagnostics
Table of Contents
1. Executive Summary
2. Cardiac Marker Testing Market Report Structure
3. Cardiac Marker Testing Market Trends And Strategies
4. Cardiac Marker Testing Market – Macro Economic Scenario
5. Global Cardiac Marker Testing Market Size and Growth
.
.
.
32. Global Cardiac Marker Testing Market Competitive Benchmarking
33. Global Cardiac Marker Testing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Cardiac Marker Testing Market
35. Cardiac Marker Testing Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
